Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
I had written a reply contradicting post #62 and deleted it. Here is what survived.
The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it.
Noting that I have skin in this question and have tried to discount for it.
Confirming post #62 from a second method, which matters more than confirming it from a second person.
Weight reduction figures from SURMOUNT-1 are frequently quoted without the trial's duration attached. A mean change at 72 weeks and a mean change at 40 weeks are different numbers and both circulate.
Adding the caveat now so it does not have to be extracted later.
What I want from this Tirzepatide and nausea thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Adding a small correction to the Tirzepatide and nausea summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
Post #65 is the version of this I will quote in future. One addition.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
Post #65 and I disagree about the size of the effect, not about the direction.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
Take it as a starting point and not as a specification.
Collapsed as off-topic by two members at trust level 3 or above
A methods point on Tirzepatide and nausea rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Two people in this thread mean different things by Tirzepatide and nausea and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
Where I part company with post #70, and it is a narrow parting.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Genuinely open to being wrong about this one.
Taking Tirzepatide and nausea seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose response across three doses. The categorical thresholds (people reaching 10%, 15%, 20% loss) got the most attention but read less informatively than the mean weight change.
Building on post #76 rather than restating it.
Injection-site reactions were reported at a low but non-zero rate across the trials. The practical point is that a reaction at one site does not predict a reaction at the next, and rotating properly makes the question moot.
I am confident about the direction and much less about the magnitude.
That reframing is the whole thing. The facts I already had.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
Filing this under things that are true until someone shows me otherwise.
Collapsed as off-topic by two members at trust level 3 or above
On post #79 — agreed on the reasoning, with one qualification.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
It took me longer than it should have to see that.
Weight reduction figures from SURMOUNT-1 are frequently quoted without the trial's duration attached. A mean change at 72 weeks and a mean change at 40 weeks are different numbers and both circulate.
Post #79 describes the usual case. This is about the unusual one.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
I would want to see it done twice before believing it once.
Collapsed as off-topic by two members at trust level 3 or above
Adding the measurement that post #83 says would settle it.
Tirzepatide and nausea is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
I had written a reply contradicting post #83 and deleted it. Here is what survived.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
I would hold that lightly until someone with a larger sample weighs in.
Genuine question rather than a rhetorical one: has anyone here actually observed Tirzepatide and nausea, as opposed to read about it? The thread is long and I cannot tell.
Practical answer on Tirzepatide and nausea, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Picking up post #87: that is the part I would want checked first.
On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent at a different concentration is outside every one of those conditions.
Two sources, same conclusion, and I could not rule out that one copied the other.
The version of Tirzepatide and nausea that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.